BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

(TheNewswire)

VANCOUVER, British Columbia, October 21, 2025 – TheNewswire - BetterLifePharma Inc. (“BetterLife” or the “Compa ny”) ( CSE:BETR / OTCQB :BETRF / FRA: NPAU ) ,an emerging biotech company, has announced that it has appointed DougDrysdale, former CEO of Cybin Inc. (“Cybin”) (NYSE: CYBN) asCorporate Advisor to advance BetterLife’s product BETR-001’s nonpsychiatric indications with focus on cluster headache and migraine.

At Cybin, Mr. Drysdale led the company’s strategy andteam build-out, taking it from molecule inception to Phase 3 trials injust three years. Mr. Drysdale is known as a vocal advocate forrevolutionizing mental healthcare through numerous speakingengagements, panel participations, and media interviews.

Earlier in his career, as Founding CEO of Alvogen, Mr.Drysdale grew the company from inception to $500 million in revenuesacross 35 countries in 5.5 years, establishing research anddevelopment (“R&D”) in New Jersey, a CRO in India, and a50-product U.S. pipeline. In 2008, he transformed NorwichPharmaceuticals, enhancing its manufacturing and R&D. In 2014, asChairman and CEO of Pernix Therapeutics, Mr. Drysdale recapitalizedthe company with $65 million, rebuilt its leadership, and grew itsenterprise value from $80 million to $800 million, raising $465million to support the turnaround. From 2017–2020, as CEO of TedorPharma, he achieved 60% revenue growth in 2019, landing it on the 2020Inc 5000 list.

Dr. Ahmad Doroudian, CEO of BetterLife, commented,“We are excited to welcome Doug to our advisory team. He is aglobally recognized leader and strategist with over 35 yearsexperience delivering multiple successful transactions in variousdifferent markets and indications.  We look forward to working withDoug to develop BETR-001 for treatment of cluster headache, migraine and neuropathic pain. BETR-001 is BetterLife’s patentedstereoisomer of 2-bromo-LSD, a non-hallucinogenic derivative of LSD.Previous forms of 2-bromo-LSD have been shown to benon-hallucinogenic, safe and tolerable in man, and in a small clinicalstudy, to cause meaningful reduction in cluster headache frequency( Karst et al, Cephalgia2010 ).

About BetterLife Pharma

BetterLife Pharma Inc.is an emerging biotechnology company primarily focused on developingand commercializing BETR-001 to treat various neurological disorders.BETR-001, which is in preclinical and IND-enabling studies, is anon-hallucinogenic and non-controlled LSD derivative in developmentand it is unique in that it is unregulated and therefore can beself-administered. BetterLife’s synthesis patent for BETR-001eliminates regulatory hurdles and its pending patent, for compositionand method of use, covers treatment of various neurological disorders,until around 2042.

BetterLife also owns a drug candidate for the treatmentof viral infections and is in the process of seeking strategicalternatives for further development.

For further information, please visit BetterLifePharma .

Contact

David Melles, Investor Relations Manager

Email: David.Melles@blifepharma.com

Phone: 1-778-887-1928

Cautionary Note RegardingForward-Looking Statements

No securities exchange has reviewed nor acceptsresponsibility for the adequacy or accuracy of the content of thisnews release. This news release contains forward-looking statementsrelating to product development, licensing, commercialization andregulatory compliance issues and other statements that are nothistorical facts. Forward-looking statements are often identified byterms such as “will”, “may”, “should”, “anticipate”,“expects” and similar expressions. All statements other thanstatements of historical fact, included in this release areforward-looking statements that involve risks and uncertainties. Therecan be no assurance that such statements will prove to be accurate andactual results and future events could differ materially from thoseanticipated in such statements. Important factors that could causeactual results to differ materially from the Company’s expectationsinclude the failure to satisfy the conditions of the relevantsecurities exchange(s) and other risks detailed from time to time inthe filings made by the Company with securities regulations. Thereader is cautioned that assumptions used in the preparation of anyforward-looking information may prove to be incorrect. Events orcircumstances may cause actual results to differ materially from thosepredicted, as a result of numerous known and unknown risks,uncertainties, and other factors, many of which are beyond the controlof the Company. The reader is cautioned not to place undue reliance onany forward-looking information. Such information, although consideredreasonable by management at the time of preparation, may prove to beincorrect and actual results may differ materially from thoseanticipated. Forward-looking statements contained in this news releaseare expressly qualified by this cautionary statement. Theforward-looking statements contained in this news release are made asof the date of this news release and the Company will update or revisepublicly any of the included forward-looking statements as expresslyrequired by applicable law.

Copyright (c) 2025 TheNewswire - All rights reserved.